Clinical Trial Update: Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age [Phase 3]

View source ↗

Summary

Phase 3 safety and efficacy study evaluating Viaskin Peanut in peanut-allergic children aged 1-3 years; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peanut Allergy

Drugs mentioned

• Viaskin Peanut (peanut epicutaneous immunotherapy patch)

Snippet

Sponsor: DBV Technologies | Conditions: Peanut Allergy | Phase 3 | Status: COMPLETED | Results posted: 2024-12-16